1. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. (February 2020) Authors: Donskov, Frede; Motzer, Robert J.; Voog, Eric; Hovey, Elizabeth; Grüllich, Carsten; Nott, Louise M.; Cuff, Katharine; Gil, Thierry; Jensen, Niels Viggo; Chevreau, Christine; Negrier, Sylvie; Depenbusch, Reinhard; Bergmann, Lothar; Cornelio, Izzy; Champsaur, Anne; Escudier, Bernard; Pal, Sumanta; ... Journal: European journal of cancer Issue: Volume 126(2020) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Temsirolimus for advanced renal cell carcinoma. Issue 1 (January 2014) Authors: Bergmann, Lothar; Maute, Luise; Guschmann, Michael Journal: Expert review of anticancer therapy Issue: Volume 14:Issue 1(2014) Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview. Issue 11 (2nd November 2021) Authors: Bergmann, Lothar; Weber, Sarah; Hartmann, Arndt; Ahrens, Marit Journal: Expert review of anticancer therapy Issue: Volume 21:Issue 11(2021) Page Start: 1273 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. (30th November 2015) Authors: Gravanis, Iordanis; Tzogani, Kyriaki; Hennik, Paula; Graeff, Pieter; Schmitt, Petra; Mueller-Berghaus, Jan; Salmonson, Tomas; Gisselbrecht, Christian; Laane, Edward; Bergmann, Lothar; Pignatti, Francesco Journal: Oncologist Issue: Volume 21:Number 1(2016) Page Start: 102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. (30th November 2015) Authors: Gravanis, Iordanis; Tzogani, Kyriaki; van Hennik, Paula; de Graeff, Pieter; Schmitt, Petra; Mueller‐Berghaus, Jan; Salmonson, Tomas; Gisselbrecht, Christian; Laane, Edward; Bergmann, Lothar; Pignatti, Francesco Journal: Oncologist Issue: Volume 21:Number 1(2016) Page Start: 102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies. Issue 16 (November 2015) Authors: Albiges, Laurence; Kube, Ulrich; Eymard, Jean-Christophe; Schmidinger, Manuela; Bamias, Aristotelis; Kelkouli, Nadia; Mraz, Bernhard; Florini, Styliani; Guderian, Gernot; Cattaneo, Agnese; Bergmann, Lothar Journal: European journal of cancer Issue: Volume 51:Issue 16(2015:Nov.) Page Start: 2368 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗